Standard BioTools (LAB) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed Standard BioTools (LAB) over the past year, losing 26.6% versus a loss of 54.3%. Over five years, LAB leads with a -86.5% price change compared with -93.0% for PACB. Pacific Biosciences of California is the larger company by market cap ($508.9 million vs $249.1 million), about 2.0 times the size.
Standard BioTools converts more of its revenue into profit, with a net margin of -87.8% versus -341.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LAB | PACB |
|---|---|---|
| Share price | $0.631 | $1.63 |
| Market cap | $249.11M | $508.95M |
| 1-day change | +2.82% | -7.39% |
| YTD return | -50.70% | -12.83% |
| 1-year return | -54.28% | -26.58% |
| 5-year return | -86.55% | -93.01% |
| EPS (TTM) | $-0.09 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $85.33M | $160.00M |
| Revenue growth (YoY) | -6.24% | +3.89% |
| Net income (latest FY) | $-74.90M | $-546.38M |
| Gross margin | 49.86% | 28.61% |
| Operating margin | -129.20% | -346.15% |
| Net margin | -87.77% | -341.47% |
| 52-week high | $1.72 | $3.44 |
| 52-week low | $0.39 | $1.07 |
| Distance from 52-week high | -63.31% | -52.62% |
| Analyst consensus | none | buy |
| Avg. price target upside | +113.95% | +68.10% |
| Average volume | 1.16M | 13.23M |
| Shares outstanding | 394.79M | 312.24M |
| Employees | 385 | 485 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pacific Biosciences of California is about 2.0 times larger than Standard BioTools by market value ($508.95M vs $249.11M).
- PACB has outperformed LAB by 27.7 percentage points over the past year.
- Standard BioTools is more profitable, keeping -87.8 cents of every revenue dollar as net income versus -341.5 cents for Pacific Biosciences of California.
- Pacific Biosciences of California grew revenue faster in its latest fiscal year (+3.89% vs -6.24%).
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
LAB vs PACB FAQ
Which is bigger, Standard BioTools or Pacific Biosciences of California?
Pacific Biosciences of California (PACB) is larger, with a market capitalization of $508.95M compared with $249.11M for Standard BioTools (LAB).
Which stock has performed better over the past year, LAB or PACB?
PACB returned -26.58% over the past 12 months, compared with -54.28% for LAB (price return, excluding dividends). Past performance does not predict future results.
Are Standard BioTools and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.